Microsoft Corp shares climbed roughly 0.7% to $459.86 in early New York trading Tuesday after Bristol Myers Squibb announced a deal to deploy the software giant’s AI-powered radiology tools aimed at accelerating early lung cancer detection. The partnership will leverage U.S. Food and Drug Administration-cleared imaging algorithms—approved for clinical use—via Microsoft’s Precision Imaging Network, which already analyzes X-ray and CT scans at hospitals across the U.S. “We have envisioned a unique AI-enabled workflow” to help clinicians identify patients and direct them to care, said Alexandra Goncalves, vice president and head of digital health at Bristol Myers.
